Evidence map›Paper›PMID 22645419›Full record

ArticleTheScientificWorldJournal2012

The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary.

Hanna Lawnicka, Dorota Ptasinska-Wnuk, Slawomir Mucha, Jolanta Kunert-Radek, Marek Pawlikowski, Henryk Stepien

Open access · goldAbstract read
In one paragraph

Article in TheScientificWorldJournal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hanna LawnickaDepartment of Immunoendocrinology, Medical University of Lodz, Dr. Sterling 3 Street, 91-425 Lodz, Poland.
Dorota Ptasinska-Wnuk
Slawomir Mucha
Jolanta Kunert-Radek
Marek Pawlikowski
Henryk Stepien
Medical University of Lodz · PLHigher School of National Economy in Kutno · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of our study was to examine the involvement of renin-angiotensin system (RAS) in estrogen-induced lactotropes proliferation and vascular endothelial growth factor (VEGF) expression in rat pituitary. The study was performed on Fisher 344 rats underwent 8-day treatment with diethylstilboestrol (DES). The proliferation index (PCNA) and VEGF expression in pituitary sections were estimated using immunohistochemical methods. Treatment with DES increased the number of PCNA-positive cells, VEGF-positive cells, and VEGF-positive blood vessels in pituitary. Stimulatory effect of estrogen on cell proliferation and VEGF expression in blood vessels was attenuated by losartan, PD123319, and captopril. VEGF immunoreactivity in pituitary cells of DES-treated rats was decreased by AT1 antagonist and not changed by AT2 blocker and ACE inhibitor. Our findings suggest the involvement of RAS in DES-induced cell proliferation and VEGF expression in pituitary. Both the AT1 and AT2 receptors appear to mediate the estrogen-dependent mitogenic and proangiogenic effects in rat pituitary.

Indexed as

Gene Expression RegulationAnimalsCaptoprilCell ProliferationDiethylstilbestrolEstrogensHyperplasiaImidazolesImmunohistochemistryLosartanMaleNeovascularization, PathologicPituitary Gland, AnteriorPyridinesRatsRats, Inbred F344CaptoprilDiethylstilbestrolEstrogensImidazolesLosartanPD 123319PyridinesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Vascular Endothelial Growth Factor A

Identifiers

PMID22645419
PMCPMC3360946
OpenAlexW1974433410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.